Search Result

Results for "

cardiac tissue

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Apoptosis (2) Biochemical Assay Reagents (2) Cathepsin (1) Ferroptosis (3) Isotope-Labeled Compounds (1) JNK (1) mAChR (1) MAP3K (1) Na+/K+ ATPase (1) Parasite (1) Potassium Channel (1) Sodium Channel (3)
By Research Areas:	Cancer (3) Cardiovascular Disease (11) Infection (1) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (5)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: MALT1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W018026

Oxfenicine L-p-Hydroxyphenylglycine; 4-Hydroxy-L-phenylglycine; UK 25842	Acyltransferase Apoptosis	Cardiovascular Disease Metabolic Disease
Oxfenicine (L-p-Hydroxyphenylglycine) is an orally active carnitine palmitoyltransferase-1 inhibitor. Oxfenicine inhibits the oxidation of fatty acids in the heart, protecting cardiac tissue from necrotic damage during ischemia, and also has an inhibitory effect on cardiac tissue apoptosis. In addition, Oxfenicine promotes lipolysis in a high-fat diet rat model. Oxfenicine can be used in the study of cardiovascular and metabolic diseases .

HY-117658

GSK-114	MAP3K	Cardiovascular Disease
GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC₅₀= 25 nM). GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC₅₀= 1 μM). Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue .

HY-P4094

CTP 1 Publications Verification	Biochemical Assay Reagents	Cardiovascular Disease
CTP is a cardiac targeting peptide. CTP transduces cardiomyocytes in vitro. CTP leads to efficient and specific transduction of heart tissue in mice model. CTP can be used to deliver therapeutic peptides, proteins and nucleic acid specifically to the heart .

HY-130272

Anti-MI/R injury agent 1	Others	Cardiovascular Disease
Anti-MI/R injury agent 1 (compound 18), a Panaxatriol derivative, is an orally active, potent anti-myocardial ischemia/reperfusion (anti-MI/R) injury agent. Anti-MI/R injury agent 1 enhances oxygen-glucose deprivation and reperfusion (OGD/R)-induced cardiomyocyte injury cell viability. Anti-MI/R injury agent 1 can markedly reduce myocardial infarction size, decrease circulating cardiac troponin I (cTnI) leakage, and alleviate cardiac tissue damage in the rats .

HY-120682

UH-AH 37	mAChR	Neurological Disease
UH-AH 37 is a muscarinic (mAChR) antagonist. UH-AH 37 exhibits a higher potency in inhibiting muscarinic responses in intestinal tissue than cardiac tissue .

HY-123251

DB-766	Parasite	Infection
DB-766 is an anti-parasite and antileishmanial agent, and is active against T. cruzi. DB-766 effectively reduces the parasite load in the blood and cardiac tissue .

HY-116759

VU0405601	Potassium Channel	Cardiovascular Disease
VU0405601 is a potent KV11.1 channel activator. VU0405601 protects cardiac tissue from dofetilide (HY-B0232)-induced ventricular tachycardia .

HY-16121

CAA-0225	Cathepsin	Others
CAA-0225 is a tissue protease L inhibitor that inhibits rat liver tissue protease L with a IC₅₀ value of 1.9 nM. CAA-0225 can participate in the degradation of autophagosome membrane markers LC3-II and GABARAP (HY-P72639), improve cardiac function in mice with reperfusion injury, and kill and eliminate Trypanosoma brucei parasites ^[1][2][3].

HY-169052

Cyy-272	JNK Apoptosis	Cardiovascular Disease Inflammation/Immunology
Cyy-272 is an orally active JNK inhibitor with IC₅₀ values of 1.25 μM for JNK1, 1.07 μM for JNK2, and 1.24 μM for JNK3. Cyy-272 exerts anti-inflammatory effects by inhibiting JNK phosphorylation, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS, HY-D1056). Additionally, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissue induced by high lipid concentrations, further mitigating cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 can be used in the study of obese cardiomyopathy .

HY-125337

SC4453	Na+/K+ ATPase	Cardiovascular Disease
SC4453 is a digoxin analogue in which the lactone ring at C17β is replaced by a pyrazine ring. SC4453 is slightly inferior to digoxin in inhibiting (Na+ + K+)-ATPase, but shows similar sensitivity to potassium ions. The differences in the sensitivity of SC4453 to heart and brain tissue from different species are mainly due to differences in its dissociation rate from the receptor. These observations confirm the high sensitivity of the human heart to cardiac glycosides.

HY-108760

Gadoterate meglumine Gd-DOTA; Magnescope; P-449	Biochemical Assay Reagents	Cardiovascular Disease Others Neurological Disease
Gadoterate meglumine (Gd-DOTA) is a non-specific paramagnetic gadolinium complex used as a contrast enhancer in magnetic resonance imaging (MRI). Gadoterate meglumine, as a contrast agent in MRI, is able to shorten the longitudinal relaxation time (T1) of tissue, resulting in a brighter signal in MRI images. Gadoterate meglumine can be used for the study of the central nervous system (such as the brain and spinal cord), abdominal, pelvic organs, breast, bone and joint imaging, angiography, and cardiac electrophysiology .

HY-B0653A

Levobupivacaine hydrochloride 2 Publications Verification (S)-(-)-Bupivacaine monohydrochloride	Sodium Channel Ferroptosis	Cardiovascular Disease Neurological Disease Cancer
Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .

HY-B0653

Levobupivacaine (S)-(-)-Bupivacaine	Sodium Channel Ferroptosis	Neurological Disease Cancer
Levobupivacaine ((S)-(-)-Bupivacaine) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .

HY-162902

ALK5-IN-82	Others	Cardiovascular Disease
ALK5-IN-82 is a potent and selective inhibitor against activin receptor-like kinase 5 (ALK5) with an IC₅₀ value of 9.1 nM. ALK5-IN-82 inhibits the protein expression of α-smooth muscle actin (α-SMA), collagen I and tissue inhibitor of metalloproteinase 1 (TIMP-1)/matrix metalloproteinase 13 (MMP-13) in transforming growth factor-β-induced human umbilical vein endothelial cells. ALK5-IN-82 is promising for research of cardiac fibrosis .

HY-B0653AS

Levobupivacaine-d9 hydrochloride (S)-(–)-Bupivacaie-d₉(hydrochloride)	Isotope-Labeled Compounds Ferroptosis Sodium Channel	Cardiovascular Disease Neurological Disease Cancer
Levobupivacaine-d₉ ((S)-(–)-Bupivacaie-d₉) hydrochloride is deuterium labeled Levobupivacaine (hydrochloride). Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .

Cat. No.	Product Name	Target	Research Area

HY-P4094

CTP 1 Publications Verification	Biochemical Assay Reagents	Cardiovascular Disease
CTP is a cardiac targeting peptide. CTP transduces cardiomyocytes in vitro. CTP leads to efficient and specific transduction of heart tissue in mice model. CTP can be used to deliver therapeutic peptides, proteins and nucleic acid specifically to the heart .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-125337

SC4453	Triterpenes Structural Classification Animals Terpenoids Source classification	Na+/K+ ATPase
SC4453 is a digoxin analogue in which the lactone ring at C17β is replaced by a pyrazine ring. SC4453 is slightly inferior to digoxin in inhibiting (Na+ + K+)-ATPase, but shows similar sensitivity to potassium ions. The differences in the sensitivity of SC4453 to heart and brain tissue from different species are mainly due to differences in its dissociation rate from the receptor. These observations confirm the high sensitivity of the human heart to cardiac glycosides.

Cat. No.	Product Name	Chemical Structure

HY-B0653AS

Levobupivacaine-d9 hydrochloride
Levobupivacaine-d₉ ((S)-(–)-Bupivacaie-d₉) hydrochloride is deuterium labeled Levobupivacaine (hydrochloride). Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .

Levobupivacaine-d9 hydrochloride

Levobupivacaine-d₉ ((S)-(–)-Bupivacaie-d₉) hydrochloride is deuterium labeled Levobupivacaine (hydrochloride). Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks